ACRX AcelRx Pharmaceuticals, Inc. Stock Quote

ACRX [NASD]

Healthcare | Drug Manufacturers - Specialty & Generic | USA

Index	-	P/E	-	EPS (ttm)	-0.36	Insider Own	1.50%	Shs Outstand	119.10M	Perf Week	-0.65%
Market Cap	179.79M	Forward P/E	16.56	EPS next Y	0.09	Insider Trans	0.00%	Shs Float	116.72M	Perf Month	49.51%
Income	-33.40M	PEG	-	EPS next Q	-0.08	Inst Own	34.80%	Short Float	11.77%	Perf Quarter	-29.36%
Sales	5.50M	P/S	32.69	EPS this Y	29.60%	Inst Trans	42.60%	Short Ratio	6.77	Perf Half Y	8.45%
Book/sh	-0.24	P/B	-	EPS next Y	133.30%	ROA	-46.50%	Target Price	-	Perf Year	18.46%
Cash/sh	0.58	P/C	2.67	EPS next 5Y	-	ROE	66.50%	52W Range	1.01 - 2.94	Perf YTD	24.19%
Dividend	-	P/FCF	-	EPS past 5Y	3.00%	ROI	120.80%	52W High	-52.21%	Beta	0.93
Dividend %	-	Quick Ratio	4.50	Sales past 5Y	-22.40%	Gross Margin	-0.40%	52W Low	39.11%	ATR	0.10
Employees	54	Current Ratio	4.60	Sales Q/Q	25.00%	Oper. Margin	-	RSI (14)	49.72	Volatility	6.22% 8.70%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	60.20%	Profit Margin	-	Rel Volume	1.32	Prev Close	1.54
Shortable	Yes	LT Debt/Eq	-	Earnings	May 17 AMC	Payout	-	Avg Volume	2.03M	Price	1.40
Recom	1.70	SMA20	0.14%	SMA50	6.46%	SMA200	-11.79%	Volume	2,096,065	Change	-8.77%

Jul-20-20

Downgrade

Credit Suisse

Neutral → Underperform

Nov-11-19

Downgrade

Credit Suisse

Outperform → Neutral

$7 → $2

Aug-05-19

Resumed

Credit Suisse

Outperform

Jul-10-19

Resumed

Credit Suisse

Outperform

Apr-24-19

Resumed

B. Riley FBR

Buy

$6.50

Feb-15-19

Initiated

Credit Suisse

Outperform

Oct-23-18

Initiated

B. Riley FBR

Buy

Oct-13-17

Reiterated

RBC Capital Mkts

Outperform

$6 → $5

Oct-13-17

Downgrade

Jefferies

Buy → Hold

Jul-14-17

Resumed

Jefferies

Buy

Sep-15-16

Reiterated

ROTH Capital

Buy

$11.25 → $15

Aug-05-16

Downgrade

Stifel

Buy → Hold

Oct-30-15

Upgrade

Jefferies

Hold → Buy

Oct-05-15

Reiterated

ROTH Capital

Buy

$8.50 → $10.50

Sep-02-15

Initiated

H.C. Wainwright

Buy

$8.50

Jul-10-15

Resumed

ROTH Capital

Buy

$7.50

May-06-15

Reiterated

Mizuho

Neutral

$5.50 → $3

May-05-15

Reiterated

RBC Capital Mkts

Outperform

$8 → $7

Mar-10-15

Reiterated

RBC Capital Mkts

Outperform

$12 → $8

Mar-09-15

Downgrade

Mizuho

Buy → Neutral

$14 → $5.59

Jun-15-21 12:45PM	Portnoy Law: Lawsuit Filed On Behalf of AcelRx Pharmaceuticals, Inc. Investors GlobeNewswire -8.77%
11:00AM	The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of AcelRx Pharmaceuticals, Inc. (ACRX) Investors Business Wire
10:00AM	ACRX Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies AcelRx Pharmaceuticals, Inc. Investors of Class Action and Encourages Investors to Contact the Firm GlobeNewswire
Jun-14-21 07:56PM	SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AcelRx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline ACRX GlobeNewswire
12:13PM	SHAREHOLDER ALERT: Robbins LLP Announces that AcelRX Pharmaceuticals, Inc. (ACRX) is Being Sued for Misleading Shareholders Business Wire
11:00AM	Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of AcelRx Pharmaceuticals, Inc. (ACRX) Investors Business Wire
11:00AM	ACRX Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies AcelRx Pharmaceuticals, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm ACCESSWIRE
Jun-13-21 11:15PM	INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
Jun-12-21 05:10PM	SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AcelRx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ACRX Newsfile
09:20AM	ROSEN, A LEADING INVESOR RIGHTS LAW FIRM, Encourages AcelRx Pharmaceuticals, Inc. Investors With LARGE LOSSES to Secure Counsel Before Important in Securities Class Action ACRX ACCESSWIRE
Jun-11-21 06:35PM	ROSEN, RESPECTED INVESTOR COUNSEL, Encourages AcelRx Pharmaceuticals, Inc. Investors With Losses to Secure Counsel Before Important August 9 Deadline in Securities Class Action - ACRX PR Newswire
01:32PM	SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
01:00PM	INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of AcelRx Pharmaceuticals, Inc. (ACRX) Investors Business Wire
10:00AM	ACRX Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies AcelRx Pharmaceuticals, Inc. Investors of Class Action and Encourages Investors to Contact the Firm ACCESSWIRE
Jun-10-21 10:24PM	SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AcelRx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline ACRX GlobeNewswire
11:00AM	Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of AcelRx Pharmaceuticals, Inc. (ACRX) on Behalf of Investors Business Wire
10:10AM	ACRX Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies AcelRx Pharmaceuticals, Inc. Investors of Class Action and Encourages Investors to Contact the Firm PR Newswire
Jun-09-21 05:00PM	The Law Offices of Frank R. Cruz Announces Investigation of AcelRx Pharmaceuticals, Inc. (ACRX) on Behalf of Investors Business Wire -8.38%
03:00PM	SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
02:56PM	INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of AcelRx Pharmaceuticals, Inc. (ACRX) on Behalf of Investors Business Wire
10:00AM	ACRX Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies AcelRx Pharmaceuticals, Inc. Investors of Class Action and Encourages Investors to Contact the Firm ACCESSWIRE
09:50AM	EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages AcelRx Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline ACRX Business Wire
Jun-08-21 10:00PM	ACELRX PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against AcelRx Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm Business Wire +7.74%
05:25PM	Pomerantz Law Firm Announces the Filing of a Class Action Against AcelRx Pharmaceuticals, Inc. and Certain Officers - ACRX PR Newswire
Jun-01-21 08:30AM	Rapid Discharge with Minimal PACU Opioids was Key Message During Presentation of DSUVIA® For Analgesia in Plastic Surgery Procedures at the California Society of Plastic Surgeons Annual Meeting PR Newswire
May-26-21 08:30AM	Presentation on the Use of DSUVIA® for Plastic Surgery Procedures Selected for "Best Papers" Session at the California Society of Plastic Surgeons Annual Meeting PR Newswire +9.76%
May-20-21 08:30AM	AcelRx Announces an Investigator-Initiated Study of DSUVIA® in the Emergency Department for Patients with Sickle Cell Disease PR Newswire +5.79%
May-17-21 04:01PM	AcelRx Pharmaceuticals Reports First Quarter 2021 Financial Results PR Newswire
02:45PM	AcelRx Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
May-15-21 09:48AM	The Week Ahead In Biotech: Sanofi, Bristol-Myers Squibb Await FDA Decisions, Earnings News Flow Tapers Off Benzinga
May-13-21 10:18AM	AcelRx's Dsuvia Shows Reduction In Postoperative Opioids Compared To Control Group Benzinga
08:30AM	Study of DSUVIA® Showing Significant Reduction in Postoperative Opioids and Better OBAS Scores Compared to Control Group to be Presented at the American Society of Regional Anesthesia (ASRA) Annual Meeting PR Newswire
May-10-21 04:05PM	AcelRx to Host First Quarter 2021 Financial Results Call and Webcast on May 17, 2021 PR Newswire
May-06-21 08:30AM	AcelRx Announces an Investigator-Initiated Study of DSUVIA® for Use in Same-Day Total Joint Replacement PR Newswire
May-03-21 03:01PM	AcelRx Pharmaceuticals (ACRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release Zacks -6.92%
Apr-08-21 10:40AM	AcelRx To Test Dsuvia In Patients On Buprenorphine Requiring A Surgical Procedure Benzinga
08:30AM	AcelRx Announces an Investigator-Initiated Study of DSUVIA® in Patients Taking Buprenorphine Who Require a Surgical Procedure PR Newswire
Mar-31-21 08:30AM	AcelRx Pharmaceuticals Announces Appointment of Marina Bozilenko to the Board of Directors PR Newswire +5.59%
Mar-29-21 09:19AM	ROCE Insights For AcelRx Pharmaceuticals Benzinga -6.59%
Mar-25-21 08:30AM	AcelRx Pharmaceuticals Announces Clinical Data Reporting High Ratings for Healthcare Professional and Patient Satisfaction Following Use of DSUVIA® for Acute Pain in Hospital Settings PR Newswire
Mar-22-21 02:48PM	AcelRx Announces Presentation and Fireside Chat at the Benzinga Biotech Small Cap Conference PR Newswire
Mar-21-21 09:53PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AcelRx Pharmaceuticals, Inc. (ACRX) Newsfile
Mar-18-21 04:43PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AcelRx Pharmaceuticals, Inc. (ACRX) PR Newswire -5.79%
Mar-16-21 10:06PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AcelRx Pharmaceuticals, Inc. (ACRX) ACCESSWIRE -14.68%
Mar-15-21 05:15PM	AcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Lags Revenue Estimates Zacks
04:54PM	AcelRx Pharmaceuticals: Q4 Earnings Insights Benzinga
04:01PM	AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results PR Newswire
02:30PM	AcelRx Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Mar-14-21 09:50PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AcelRx Pharmaceuticals, Inc. (ACRX) Newsfile
08:14AM	Week Ahead In Biotech (March 14-20): Update On Fibrogen-AstraZeneca's Anemia Drug, Earnings and Presentations Benzinga
Mar-12-21 05:45AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AcelRx Pharmaceuticals, Inc. (ACRX) PR Newswire
Mar-09-21 10:30PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AcelRx Pharmaceuticals, Inc. (ACRX) ACCESSWIRE +10.73%
10:45AM	2 Penny Stocks That Could Make You Filthy Rich Motley Fool
Mar-08-21 04:05PM	AcelRx to Host Fourth Quarter and Full Year 2020 Financial Results Call and Webcast on March 15, 2021 PR Newswire
12:30PM	Will AcelRx Pharmaceuticals (ACRX) Report Negative Q4 Earnings? What You Should Know Zacks
Mar-07-21 05:56PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AcelRx Pharmaceuticals, Inc. (ACRX) Newsfile
Mar-03-21 03:00AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AcelRx Pharmaceuticals, Inc. (ACRX) PR Newswire
Feb-22-21 01:46PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AcelRx Pharmaceuticals, Inc. (ACRX) Newsfile
Feb-20-21 07:00PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AcelRx Pharmaceuticals, Inc. (ACRX) ACCESSWIRE
Feb-18-21 09:47PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AcelRx Pharmaceuticals, Inc. (ACRX) PR Newswire
Feb-17-21 08:30AM	AcelRx Announces an Investigator-Initiated Study of DSUVIA® in Patients Undergoing Plastic Surgery Procedures PR Newswire
Feb-04-21 11:40PM	When Will AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Become Profitable? Simply Wall St.
Jan-26-21 10:04AM	ROCE Insights For AcelRx Pharmaceuticals Benzinga
Jan-20-21 09:00AM	AcelRx Announces Pricing of $27.5 Million Public Offering of Common Stock PR Newswire -17.02%
Jan-19-21 04:01PM	AcelRx Announces Underwritten Public Offering of Common Stock PR Newswire +12.98%
08:30AM	AcelRx Announces an Investigator-Initiated Study of DSUVIA® in Cardiac Surgery Enhanced Recovery Regimen PR Newswire
Jan-14-21 08:30AM	AcelRx Announces Year-End 2020 Metrics and Review of 2020 Achievements PR Newswire -6.53%
Jan-13-21 10:30AM	ROCE Insights For AcelRx Pharmaceuticals Benzinga -8.72%
08:40AM	Do Options Traders Know Something About AcelRx (ACRX) Stock We Don't? Zacks
Jan-12-21 11:39AM	These 2 Penny Stocks Could Surge Over 300%, Say Analysts TipRanks +60.29%
Dec-10-20 09:00AM	AcelRx Pharmaceuticals Announces Publication of Clinical Data on Decreased Postoperative Opioid Requirements and Enhanced Postanesthesia Recovery Following Perioperative Use of DSUVIA® PR Newswire
08:30AM	AcelRx Announces $10 Million Registered Direct Common Stock Offering PR Newswire
Dec-09-20 12:20PM	AcelRx Pharmaceuticals to Present at LD Micro Main Event PR Newswire
Dec-04-20 08:30AM	AcelRx Pharmaceuticals Announces Partnership with the National Rural Health Association PR Newswire +6.29%
Dec-02-20 10:58AM	Is AcelRx Pharmaceuticals (ACRX) A Good Stock To Buy Now? Insider Monkey
Nov-18-20 08:30AM	AcelRx Pharmaceuticals Announces Commentary in Practical Pain Management on Previously Published Clinical Data on Preoperative Administration of DSUVIA® PR Newswire
Nov-07-20 07:08AM	Analysts Are Upgrading AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) After Its Latest Results Simply Wall St.
Nov-06-20 01:28PM	AcelRx Pharmaceuticals to Present at Credit Suisse 29th Annual Virtual Healthcare Conference PR Newswire -22.46%
Nov-05-20 08:20PM	AcelRx Pharmaceuticals (ACRX) Reports Q3 Loss, Misses Revenue Estimates Zacks
04:05PM	AcelRx Pharmaceuticals Reports Third Quarter 2020 Financial Results PR Newswire
02:30PM	AcelRx Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Oct-29-20 04:05PM	AcelRx to Host Third Quarter 2020 Financial Results Call and Webcast on Thursday, November 5, 2020 PR Newswire
Oct-28-20 12:33PM	AcelRx Pharmaceuticals (ACRX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Zacks
Oct-21-20 10:46AM	Aclaris (ACRS) Begins Phase II Study on Eczema Candidate Zacks
Oct-15-20 10:26AM	RedHill's (RDHL) RHB-204 Gets FDA Orphan Drug Designation Zacks -9.19%
Oct-13-20 12:00PM	AcelRx Pharmaceuticals (ACRX) Upgraded to Buy: Here's Why Zacks
08:44AM	AcelRx (ACRX) Looks Good: Stock Adds 5.3% in Session Zacks
Oct-12-20 08:59AM	Is the Options Market Predicting a Spike in AcelRx (ACRX) Stock? Zacks +5.32%
Sep-29-20 08:30AM	AcelRx to Host Virtual KOL Event on Perioperative Use of DSUVIA® PR Newswire -6.54%
Sep-23-20 06:48AM	Reflecting on AcelRx Pharmaceuticals' (NASDAQ:ACRX) Share Price Returns Over The Last Three Years Simply Wall St. -13.31%
Sep-22-20 08:30AM	AcelRx Awarded U.S. Army Contract for DSUVIA® PR Newswire
Sep-14-20 08:30AM	AcelRx Announces DSUVIA® Added to the U.S. Department of Defense's Joint Deployment Formulary PR Newswire +17.76%
Sep-10-20 04:05PM	AcelRx Pharmaceuticals to Present at Two Upcoming Conferences PR Newswire -5.22%
Aug-31-20 05:00PM	LD Micro - 360 Companies Set to Present this Week ACCESSWIRE
Aug-24-20 08:30AM	AcelRx Announces an Investigator-Initiated Study of DSUVIA® in Orthopedic Patients in the Perioperative Setting PR Newswire -7.30%
Aug-19-20 08:30AM	AcelRx Pharmaceuticals Announces Publication of Clinical Data on Reduced Opioid Use and Reduced Time in the Postanesthesia Care Unit (PACU) Following Preoperative Administration of DSUVIA® PR Newswire +14.52%
Aug-11-20 12:00PM	AcelRx Pharmaceuticals (ACRX) Moves to Buy: Rationale Behind the Upgrade Zacks -11.59%
Aug-10-20 05:45PM	AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Lags Revenue Estimates Zacks
04:01PM	AcelRx Pharmaceuticals Reports Second Quarter 2020 Financial Results PR Newswire
Aug-03-20 04:05PM	AcelRx to Host Second Quarter 2020 Financial Results Call and Webcast on Monday, August 10th, 2020 PR Newswire

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. It also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience